Investment Analysts’ Recent Ratings Updates for Johnson & Johnson (JNJ)

Several brokerages have updated their recommendations and price targets on shares of Johnson & Johnson (NYSE: JNJ) in the last few weeks:

• 4/24/2026 – Johnson & Johnson was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
• 4/20/2026 – Johnson & Johnson had its price target raised by Guggenheim from $244.00 to $266.00. They now have a “buy” rating on the stock.
• 4/16/2026 – Johnson & Johnson had its price target raised by Argus from $240.00 to $275.00. They now have a “buy” rating on the stock.
• 4/16/2026 – Johnson & Johnson had its price target raised by Daiwa Securities Group Inc. from $237.00 to $246.00. They now have an “outperform” rating on the stock.
• 4/15/2026 – Johnson & Johnson was given a new $283.00 price target by Morgan Stanley.
• 4/15/2026 – Johnson & Johnson had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $265.00 price target on the stock.
• 4/15/2026 – Johnson & Johnson had its price target raised by Stifel Nicolaus from $220.00 to $250.00. They now have a “hold” rating on the stock.
• 4/15/2026 – Johnson & Johnson had its price target raised by Barclays PLC from $234.00 to $255.00. They now have an “equal weight” rating on the stock.
• 4/15/2026 – Johnson & Johnson had its price target raised by Bank of America Corporation from $253.00 to $254.00. They now have a “neutral” rating on the stock.
• 4/15/2026 – Johnson & Johnson had its price target raised by Raymond James Financial, Inc. from $237.00 to $258.00. They now have an “outperform” rating on the stock.
• 4/15/2026 – Johnson & Johnson had its price target raised by Leerink Partners from $232.00 to $252.00. They now have a “market perform” rating on the stock.
• 4/15/2026 – Johnson & Johnson had its price target raised by JPMorgan Chase & Co. from $250.00 to $260.00. They now have a “neutral” rating on the stock.
• 4/15/2026 – Johnson & Johnson had its price target raised by Sanford C. Bernstein from $225.00 to $251.00. They now have a “market perform” rating on the stock.
• 4/15/2026 – Johnson & Johnson had its price target raised by Wells Fargo & Company from $240.00 to $263.00. They now have an “overweight” rating on the stock.
• 4/15/2026 – Johnson & Johnson had its price target raised by The Goldman Sachs Group, Inc. from $265.00 to $275.00. They now have a “buy” rating on the stock.
• 4/10/2026 – Johnson & Johnson had its price target raised by Morgan Stanley from $262.00 to $267.00. They now have an “overweight” rating on the stock.
• 4/8/2026 – Johnson & Johnson is now covered by TD Cowen. They set a “buy” rating and a $250.00 price target on the stock.
• 4/7/2026 – Johnson & Johnson had its price target raised by Guggenheim from $240.00 to $244.00. They now have a “buy” rating on the stock.
• 4/7/2026 – Johnson & Johnson had its price target raised by Citigroup Inc. from $274.00 to $285.00. They now have a “buy” rating on the stock.
• 3/30/2026 – Johnson & Johnson had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $255.00 price target on the stock.
• 3/19/2026 – Johnson & Johnson had its price target raised by Barclays PLC from $217.00 to $234.00. They now have an “equal weight” rating on the stock.
• 3/18/2026 – Johnson & Johnson was given a new $253.00 price target by Morgan Stanley.
• 3/18/2026 – Johnson & Johnson had its “overweight” rating reaffirmed by Morgan Stanley.
• 3/17/2026 – Johnson & Johnson had its price target raised by HSBC Holdings plc from $265.00 to $280.00. They now have a “buy” rating on the stock.
• 3/11/2026 – Johnson & Johnson had its price target raised by Citigroup Inc. from $250.00 to $274.00. They now have a “buy” rating on the stock.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio is 60.12%.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 30,142 shares of company stock worth $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.